Eluvia Drug-Eluting Vascular Stent


Ranger Paclitaxel-Coated PTA Balloon Catheter

Resources › Data Sheets :

Data Sheets



View the remarkable results Eluvia achieved in the first head-to-head trial: Eluvia DES vs. Zilver PTX.

2-Year Follow-up Data Sheet

2-year results from IMPERIAL

Evaluate the safety and effectiveness of the Boston Scientific Corporation ELUVIA™ Drug-Eluting Vascular Stent System for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length.

RANGER II SFA Pivotal Trial Data Sheet

RANGER II SFA Pivotal Trial Data Sheet

See the 12-month full cohort results of the Ranger II SFA Pivotal Trial.

COMPARE Clinical Trial

COMPARE Clinical Data Sheet

Learn more about the world’s first head-to-head, prospective, multi-center Randomized Controlled Trial (1:1) comparing the lower dose Paclitaxel RANGER DCB (2 µg/mm2) to the higher dose Paclitaxel IN.PACT DCB (3.5 µg/mm2).

COMPARE Manuscript published in the European Heart Journal. January 2020.
Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

1. Kaplan Meier Estimate; Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.

2. Versus 87.0% primary patency in the none/mild calcium arm of the IMPERIAL Calcium Subgroup.